New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
10:55 EDTABT, ABT, AZN, AZN, CELG, CELG, INCY, INCY, LLY, LLY, PFE, PFE, RIGL, RIGLLeerink's major pharmaceuticals and biotech analysts hold a conference call
Major Pharmaceuticals Analyst Fernandez and Biotech Analysts Kozul and Liang provide insights from the American College of Rheumatology's Annual Meeting on an Analyst/Industry conference call. Relevant covered companies ABT, AZN, CELG, INCY, LLY, PFE and RIGL may be included on the Analyst/Industry conference call to be held on November 14 at 11 am.
News For ABT;AZN;CELG;INCY;LLY;PFE;RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 19, 2015
07:05 EDTINCYIncyte says EVP, Chief Commercial Officer Jim Daly to leave at end of June
Subscribe for More Information
June 18, 2015
11:53 EDTINCYIncyte management to meet with SunTrust
Subscribe for More Information
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
07:36 EDTAZNReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
06:55 EDTINCYIncyte management to meet with JMP Securities
Meetings to be held in New York on June 18 and in Boston on June 19 hosted by JMP Securities.
06:09 EDTABTTeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
June 17, 2015
12:02 EDTLLYEli Lilly reports LY2951742 meets primary endpoint in Phase 2b migraine study
Eli Lilly announced that its investigational medicine for prevention of migraine -- LY2951742, a CGRP neutralizing antibody -- met the primary endpoint in a Phase 2b study in episodic migraine. The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of four different doses of LY2951742 given in a once-monthly, subcutaneous injection in more than 400 patients with episodic migraine. The primary objective was to assess whether at least one dose of LY2951742 was superior to placebo in the prevention of migraine headache. LY2951742 demonstrated a statistically significant reduction in migraine headache days and a safety and tolerability profile confirming the previous results seen in a Phase 2a study. In addition to the migraine program, Lilly has initiated two Phase 3 trials with LY2951742 in patients suffering from cluster headache. Based on the unmet medical need and significance of this disorder for patients, Lilly has been granted fast track designation from the U.S. FDA for cluster headache.
10:00 EDTPFE, LLYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:10 EDTLLYEli Lilly and Dana-Farber Cancer Institute enter research collaboration
Subscribe for More Information
08:02 EDTLLYEli Lilly partnering with Sarah Cannon Research Institute for oncology therapy
Eli Lilly and Sarah Cannon Research Institute announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
07:32 EDTCELGCelgene announces additional $4B share repurchase authorization
Celgene Corporation announced that during its June meeting the company's Board of Directors authorized the repurchase of up to an additional $4B of the company's common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene's management and in accordance with the requirements of the Securities and Exchange Commission. Celgene now has a total of approximately $5.2B remaining from previous authorizations plus the new authorization. Since 2009, Celgene has returned approximately $12.3B to shareholders through the repurchase program.
07:25 EDTLLY, PFEPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
05:31 EDTLLYEli Lilly initiated with an Overweight at Piper Jaffray
Subscribe for More Information
June 16, 2015
14:23 EDTAZNReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptosí pipeline, and maintains an Outperform rating on the stock.
14:12 EDTABTAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
11:06 EDTABTTeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
09:21 EDTABTMylan issues statement regarding Abbott's support for Perrigo transaction
Subscribe for More Information
09:10 EDTABTAbbott confirms support for Mylan's proposed acquisition of Perrigo
Abbott (BT) confirmed its continued support for Mylan (MYL) N.V's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo (PRGO). "We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come," said Abbott. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction."
08:36 EDTLLYEli Lilly price target raised to $100 from $87 at Jefferies
Jefferies raised its price target for Eli Lilly shares to $100 saying that while the market is "overly-obsessed" on the EXPEDITION-EXT abstract for Alzheimer's, the potential for cholesterol treatment evacetrapib should begin to be realized over the next 12 months. Jefferies keeps a Buy rating on Lilly.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use